主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文单位:Graduate School Zunyi Medical University Guizhou Province Zunyi 563003 China
英文关键词:Acutecerebralinfarction;Tirofiban;Intravenousthrombolysis;Endovasculartreatment
急性脑梗死是指因脑局部缺血缺氧所导致的神经功能障碍性疾病,抗血小板治疗在急性脑梗死的治疗和二级预防中应用已达成共识。新型抗血小板聚集药物血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂如替罗非班在心血管疾病应用中的安全性及有效性已得到大量临床研究认可。但对于替罗非班在急性脑梗死的应用仍存在争议,现将替罗非班在急性脑梗死中的应用进展进行综述。
Acute cerebral infarction refers to the neurological dysfunction disease caused by cerebral ischemia and hypoxia. The application of antiplatelet therapy in the treatment and secondary prevention of acute cerebral infarction has became a consensus. The safety and efficacy of platelet glycoprotein Ⅱb/Ⅲa receptor antagonists such as tirofiban in the application of cardiovascular diseases have been recognized by a large number of clinical researches. However, the application of tirofiban in acute cerebral infarction is still controversial. This paper reviews the application progress of tirofiban in acute cerebral infarction.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。